Related Experiment Video
Updated: Apr 5, 2026
Surgical Angiogenesis in Porcine Tibial Allotransplantation: A New Large Animal Bone Vascularized Composite Allotransplantation Model
Published on: August 13, 2017
Mycophenolate mofetil therapy for severe immune thrombocytopenia
Alice Taylor1, Lucy Neave2, Shalini Solanki3
1University College London Hospitals NHS Foundation Trust, London, UK.
Abstract:
Severe immune thrombocytopenia purpura (ITP) presents a clinical challenge. Second-line treatment options are variable without a precise protocol. We present 46 severe ITP patients treated with mycophenolate mofetil (MMF), retrospectively identified from three London teaching hospitals. Data was collected on patient demographics, co-morbidities and previous treatment strategies. Our key interest was whether there was a sustained response in platelet count to MMF. Patients included 27 males and 19 females whose ages ranged from 19 to 93 years old (median 52·5 years). Twenty-nine had primary ITP and 17 had secondary ITP, a third of whom had viral-associated disease. The standard dose of MMF was 1 g/day. Twenty-four patients (52%) responded with 15 (33%) achieving a complete response. No active viral-associated ITP patients demonstrated a response to MMF, although numbers were small (n = 4). We were not able to demonstrate a difference between responders and non-responders based on gender, age, previous therapies or time since diagnosis of ITP. Three of four previously splenectomized patients responded, two achieving complete response. We conclude that MMF is a useful steroid-sparing immunosuppressant to be considered in the second-line or later treatment of ITP.
Insights
Mycophenolate mofetil (MMF) shows promise as a second-line treatment for severe immune thrombocytopenia purpura (ITP). Over half of patients responded, with a third achieving complete remission, indicating MMF
Area of Science:
- Hematology
- Immunology
- Pharmacology
Background:
- Severe immune thrombocytopenia purpura (ITP) poses significant clinical challenges with variable second-line treatment options.
- Establishing effective and well-tolerated treatment protocols for ITP is crucial for patient management.
Purpose of the Study:
- To evaluate the efficacy of mycophenolate mofetil (MMF) as a second-line treatment for severe immune thrombocytopenia purpura (ITP).
- To assess sustained platelet count response in ITP patients treated with MMF.
Main Methods:
- Retrospective analysis of 46 severe ITP patients treated with MMF (1g/day) across three London teaching hospitals.
- Data collection included patient demographics, comorbidities, prior treatments, and platelet count responses.
- Analysis focused on sustained platelet response rates and factors influencing treatment outcomes.
Main Results:
- Overall, 52% of patients (24/46) responded to MMF, with 33% (15/46) achieving a complete response.
- No response was observed in the small cohort of active viral-associated ITP patients (n=4).
- No significant differences in response rates were found based on gender, age, previous therapies, or time since diagnosis.
Conclusions:
- Mycophenolate mofetil (MMF) is a viable steroid-sparing immunosuppressant for second-line or later treatment of ITP.
- MMF demonstrates potential in improving platelet counts in patients with severe ITP.
- Further research may be warranted to explore MMF's efficacy in specific ITP subtypes.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:27Tumor Immunotherapy